Becky Voorheis

Becky Voorheis is CEO and co-founder of Quickbeam, Inc. — a startup drug development company in Beaverton, Oregon which holds an exclusive license from OHSU to a family of novel VMAT-2 inhibiting compounds developed for the treatment of methamphetamine addiction. Becky has over 18 years of experience in strategic investments, mergers & acquisitions, in- and out-licensing, and business development in both high-tech and life sciences. Prior to Quickbeam, she was the VP of business development for Apexian Pharmaceuticals, a startup biotech with a portfolio of anti-cancer therapeutics out of Indianapolis, Indiana, where Becky helped the company raise multiple millions in investment capital. Before Apexian, she was VP of investments for a life sciences venture capital fund, group director of mergers & acquisitions at Cadence Design Systems, and senior manager of strategic investments for Intel Capital. Becky has a BA from Swarthmore College and an MBA from Duke University. She lives in Beaverton, Oregon with her husband, two children, and big, sleepy dog.